Dr. Priya Choudhry
University of California, USA
Email: [email protected], [email protected]
Qualifications
2011 Ph.D., Oncological
Sciences, University of Utah, USA
2005 B.Sc., Biotechnology,
GGSIP University, India
Publications (Selected)
-
Choudhry, P., Kasap, C., Patiño-Escobar, B., Gugliemini, O., Geng, H., Sarin, V., ... & Wiita, A. P. (2024). Functional multiomics reveals genetic and pharmacologic regulation of surface CD38 in multiple myeloma. Blood Neoplasia, 1(3), 100025.
-
Griffin, M. E., Thompson, J. W., Xiao, Y., Sweredoski, M. J., Aksenfeld, R. B., Jensen, E. H., ... & Hsieh-Wilson, L. C. (2023). Functional glycoproteomics by integrated network assembly and partitioning. bioRxiv.
-
Ferguson, I. D., Patiño-Escobar, B., Tuomivaara, S. T., Lin, Y. H. T., Nix, M. A., Leung, K. K., ... & Wiita, A. P. (2022). The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance. Nature communications, 13(1), 4121.
-
McMillan, A., Haioun, C., Sancho, J. M., Viardot, A., Izquierdo, A. R., Martin, E. D., ... & Matasar, M. (2022). P1189: Initial safety run-in results of the phase iii polargo trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients with relapsed/refractory DIFFUSE LARGE B-CELL lymphoma. HemaSphere, 6, 1075-1076.
-
Matasar, M. J., Haioun, C., Sancho, J. M., Viardot, A., Rodriguez Izquierdo, A., Donato Martin, E. M., ... & McMillan, A. (2022). Initial safety run-in results of the phase III POLARGO trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
-
Ferguson, I. D., Escobar, B. P., Tuomivaara, S. T., Lin, Y. H. T., Nix, M. A., Leung, K. K., ... & Wiita, A. P. (2021). Defining the cell surface proteomic landscape of multiple myeloma reveals immunotherapeutic strategies and biomarkers of drug resistance. BioRxiv, 2021-01.
-
Kambhampati, S., Wong, S. W., Martin III, T., Wolf, J. L., Choudhry, P., Karlon, W., ... & Shah, N. (2020). Phase II Study of Daratumumab in Combination with Azacitidine and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Daratumumab: Darazadex. Blood, 136, 27-28.
-
Ramkumar, P., Abarientos, A. B., Tian, R., Seyler, M., Leong, J. T., Chen, M., ... & Kampmann, M. (2020). CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma. Blood advances, 4(13), 2899-2911.
-
Huang, H. H., Ferguson, I. D., Thornton, A. M., Bastola, P., Lam, C., Lin, Y. H. T., ... & Wiita, A. P. (2020). Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma. Nature communications, 11(1), 1931.
-
Choudhry, P., Mariano, M. C., Geng, H., Martin III, T. G., Wolf, J. L., Wong, S. W., ... & Wiita, A. P. (2020). DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma. Leukemia, 34(3), 938-941.
-
Lorentsen, K., Sankaran, P., Trinklein, N. D., Pham, D., Schellenberger, U., Buelow, B., ... & Aldred, S. F. (2019). Uncoupling tumor-cell cytotoxicity from cytokine release with novel T-cell engaging bispecific antibodies. Cancer Research, 79(13_Supplement), 1554-1554.
-
Choudhry, P., Mariano, M. C., & Wiita, A. P. (2018). DNA methyltransferase inhibitors increase expression of CD38 and enhance daratumumab efficacy in multiple myeloma. Blood, 132, 5618.
-
Choudhry, P., Galligan, D., & Wiita, A. P. (2018). Seeking convergence and cure with new myeloma therapies. Trends in cancer, 4(8), 567-582.
-
Buelow, B., Pham, D., Choudhry, P., Dang, K., Pratap, P., Clarke, S., ... & Van Schooten, W. (2017). T cell engagement without cytokine storm: a novel BCMA x CD3 antibody killing myeloma cells with minimal cytokine secretion. Blood, 130, 501.
Profile Details
WoS ResearcherID: F-7576-2014
https://www.linkedin.com/in/priyachoudhry
https://scholar.google.com/citations?user=gsdedYAAAAAJ&hl=en
https://www.researchgate.net/profile/Priya-Choudhry